A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

• Main Authors: Kei Fukuhara (Author), Kenichi Furihata (Author), Nobushige Matsuoka (Author), Rio Itamura (Author), Vesper Ramos (Author), Toshiaki Hagi (Author), Hindu Kalluru (Author), Candace Bramson (Author), Steven G. Terra (Author), Jing Liu (Author)
• Format: Book
• Published: Wiley, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Vupanorsen (PF‐07285557) is a second‐generation tri‐N‐acetyl galactosamine (GalNAc3)‐antisense oligonucleotide targeted to angiopoietin‐like 3 (ANGPTL3) mRNA, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. To aid bringing innovative drugs to global patients effici...